{"filing":{"accession_number":"0001193125-26-350568","cik":"0001662774","ticker":"QNCX","company_name":"Quince Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"d163839d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526350568/d163839d8k.htm"},"events":[{"id":27759,"run_id":25333,"accession_number":"0001193125-26-350568","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) discloses financial results including R\u0026D expense ($5.5M), G\u0026A expense ($16.6M), and net loss ($75.5M), along with cash position ($116M) and operational highlights. The disclosure is material as it reports significant financial results and strategic developments including the completed Orphai acquisition and private placement financing.","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29425,"accession_number":"0001193125-26-350568","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) discloses financial results including R\u0026D expense ($5.5M), G\u0026A expense ($16.6M), and net loss ($75.5M), along with cash position ($116M) and operational highlights. The disclosure is material as it reports significant financial results and strategic developments including the completed Orphai acquisition and private placement financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:22:48.895612+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29425,"accession_number":"0001193125-26-350568","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) discloses financial results including R\u0026D expense ($5.5M), G\u0026A expense ($16.6M), and net loss ($75.5M), along with cash position ($116M) and operational highlights. The disclosure is material as it reports significant financial results and strategic developments including the completed Orphai acquisition and private placement financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:22:48.895612+00:00","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-08-14"}]}